

## Special Issue

# Diagnostic and Predictive Tissue Markers in GI Cancers

### Message from the Guest Editor

Dear colleagues, The recent advancements in systemic targeted therapies for cancer have not only made necessary the identification of new diagnostic and predictive tissue markers for different malignant neoplasms but also the need to offer the best standardization for immunohistochemical and molecular biology techniques. Histopathology and molecular pathology units can and must provide real indications for patients' prognosis and best therapeutic options. The aim of this Special Issue is to focus on the identification, feasibility, and reproducibility of recent tissue markers in GI tumors. The Special Issue, launched by *Cancers*, is dedicated to answering diagnostic and biological unsolved questions in GI cancers. Researchers are also encouraged to submit original research on new insights for known and well-established markers in the pathological mechanisms and molecular pathways of neoplasms of the GI tract, pancreas, liver, and biliary tract. Review articles describing the state of the art and systematic reviews on this topic are also encouraged.

### Guest Editor

Dr. Francesco Vasuri

Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna,  
Via Albertoni 15, 40138 Bologna, Italy

### Deadline for manuscript submissions

closed (15 July 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/50702](https://mdpi.com/si/50702)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)